《ET Net News Agency, 7th Special Report》After surging approximately 7.67% yesterday, Genscript Biotech (01548) immediately retreated by 14.5% today, closing at HK$42. The stock traded about 6.34 million shares, involving HK$266 million.
The 2026 Nobel Prize in Physiology or Medicine was awarded to Karl Deisseroth, Peter Hegemann, and Georg Nagel for their outstanding discoveries in "light-gated ion channels and optogenetics." Among the laureates, Georg Nagel currently serves as a scientific advisor to Zhongmou Medical Technology (Shanghai), an indirectly invested company of Genscript Biotech.
Zhongmou Medical is held with an 11.88% stake by Nanjing Hua Tai Genscript Biopharmaceuticals, a company in which Genscript Biotech's wholly-owned subsidiary, Genscript Technologies (Nanjing), holds a 19% stake. According to the company's introduction, Zhongmou Medical is an innovative biotech company at the clinical registration stage, advancing global registration clinical trials, dedicated to restoring visual function for patients with retinal degenerative diseases using an optogenetics platform technology. The company focuses on innovative drug development in the retinal field and extends its reach into related neurodegenerative diseases.
The Hang Seng Index closed at 24,164, down 115 points or 0.5%, with main board turnover exceeding HK$10.8 billion. The Hang Seng China Enterprises Index stood at 8,086, down 42 points or 0.5%. The Hang Seng Tech Index closed at 4,191, down 31 points or 0.7%. (nw)
The 2026 Nobel Prize in Physiology or Medicine was awarded to Karl Deisseroth, Peter Hegemann, and Georg Nagel for their outstanding discoveries in "light-gated ion channels and optogenetics." Among the laureates, Georg Nagel currently serves as a scientific advisor to Zhongmou Medical Technology (Shanghai), an indirectly invested company of Genscript Biotech.
Zhongmou Medical is held with an 11.88% stake by Nanjing Hua Tai Genscript Biopharmaceuticals, a company in which Genscript Biotech's wholly-owned subsidiary, Genscript Technologies (Nanjing), holds a 19% stake. According to the company's introduction, Zhongmou Medical is an innovative biotech company at the clinical registration stage, advancing global registration clinical trials, dedicated to restoring visual function for patients with retinal degenerative diseases using an optogenetics platform technology. The company focuses on innovative drug development in the retinal field and extends its reach into related neurodegenerative diseases.
The Hang Seng Index closed at 24,164, down 115 points or 0.5%, with main board turnover exceeding HK$10.8 billion. The Hang Seng China Enterprises Index stood at 8,086, down 42 points or 0.5%. The Hang Seng Tech Index closed at 4,191, down 31 points or 0.7%. (nw)
